Castle Biosciences, Inc. CSTL
$35.18
$1.745.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.42M | -12.83M | -24.16M | -12.24M | -9.47M |
| Total Depreciation and Amortization | -4.51M | 14.94M | 20.67M | 22.66M | 42.49M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 59.31M | 31.53M | 54.23M | 49.74M | 38.58M |
| Change in Net Operating Assets | 7.25M | 14.62M | 13.60M | 1.62M | -9.11M |
| Cash from Operations | 42.63M | 48.25M | 64.35M | 61.78M | 62.49M |
| Capital Expenditure | -43.12M | -43.74M | -36.02M | -36.40M | -27.95M |
| Sale of Property, Plant, and Equipment | 37.00K | 43.00K | 45.00K | 47.00K | 32.00K |
| Cash Acquisitions | -1.00K | -18.73M | -18.73M | -18.73M | -18.73M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -8.24M | -1.32M | -5.66M | -8.35M | -13.19M |
| Cash from Investing | -51.32M | -63.74M | -60.37M | -63.43M | -59.83M |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -106.00K | -113.00K | -115.00K | -114.00K | -107.00K |
| Issuance of Common Stock | 5.62M | 5.22M | 4.62M | 2.84M | 4.70M |
| Repurchase of Common Stock | -15.94M | -15.74M | -11.66M | -10.67M | -10.78M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.00M | 190.00K | 190.00K | 190.00K | 190.00K |
| Cash from Financing | -11.43M | -10.44M | -6.96M | -7.76M | -6.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -20.12M | -25.93M | -2.98M | -9.40M | -3.34M |